Bulletin Today | Personal HealthBy Jesse J. Holland and Linda A. Johnson of The Associated Press WASHINGTON (AP) — The Supreme Court struggled Monday with whether it should allow federal officials to challenge deals between pharmaceutical corporations and their generic drug competitors that the government says could keep cheaper forms of medicine off the American market for longer periods of time. Justices heard arguments from the Justice Department against what they call “pay-for-delay” deals or “reverse settlements.” Such deals arise when generic companies file …